JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions.Three isoforms of the serine/threonine protein kinase JNK family (JNK1, JNK2, and JNK3) exist. JNKs play a role in the development and progression of many pathologies, including cancer, inflammatory diseases, cardiovascular and metabolic disorders, and neurodegenerative diseases.
JNKs are triggered by a phosphorylation cascade that typically involves two different upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). This process is similar to that used to activate the other MAP kinases. JNKs are triggered by MKK4 and MKK7 at the MAP2K level; the former is a shared activator of the JNK and p38 MAP kinase signaling pathways. The JNK cascade is a component of a complicated signaling network since it crosses numerous other routes at different places.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V74393 | JNK-IN-13 | 345986-38-1 | JNK-IN-13 (compound 1) is a potent and specific JNK inhibitor (antagonist) with IC50s of 290 nM and 500 nM for JNK3 and JNK2, respectively. | |
V85692 | JNK-IN-15, Cell-Permeable | |||
V85683 | JNK-IN-15, Cell-Permeable, Negative Control | |||
V12253 | JNK-IN-7 | 1408064-71-0 | JNK-IN-7 is a potent JNK inhibitor, inhibiting JNK1, JNK2 and JNK3 with IC50 of 1.5, 2 and 0.7 nM respectively. | |
V0472 | JNK-IN-8 | 1410880-22-6 | JNK-IN-8 (JNK Inhibitor XVI; JNK-IN8) is the first irreversible/covalent inhibitor of pan-JNK (c-Jun N-terminal Kinase) with potential antitumor activity. | |
V78318 | JNK2-IN-1 | JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 Μm). | ||
V74392 | JNK3 inhibitor-3 | 2873465-25-7 | JNK3 inhibitor-3 (compound 15g) is a selective, BBB (blood-brain barrier) penetrating, orally bioactive c-Jun N-terminal kinase 3 (JNK3) inhibitor. | |
V80457 | JNK3 inhibitor-6 | JNK3 inhibitor-6 (Compound A53) is a selective JNK3 inhibitor (IC50=78 nM). | ||
V80458 | JNK3 inhibitor-8 | JNK3 inhibitor-8 is a specific, orally bioactive JNK3 inhibitor that can cross the BBB (blood-brain barrier). | ||
V9844 | KB-R7943 mesylate | 182004-65-5 | KB-R7943 mesylate, the mesylate salt of KB-R-7943, is a novel and potent reverse Na(+) /Ca(2+) exchanger (NCX(rev)) with neuroprotective action. | |
V51552 | L-JNKI-1 | L-JNKI-1 is a cell-penetrable peptide inhibitor of JNK. | ||
V24419 | Loureirin B | 119425-90-0 | Loureirin B is a novel and potent bioactive compound. | |
V74394 | n-Butyl α-D-fructofuranoside | 80971-59-1 | n-Butyl α-D-fructofuranoside is extracted from the root bark of Ulmus davidiana var. | |
V9935 | RPI-1 | 269730-03-2 | RPI-1 is an ATP-dependent RET kinase inhibitor. | |
V51131 | SP-600125-Me | 54642-23-8 | negative control for SP-600125 | |
V0471 | SP600125 (SP600125; NSC75890) | 129-56-6 | SP600125 (SP6-00125; NSC-75890) is a cell-permeable, broad-spectrum, reversible and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with potential anticancer and anti-inflammatory activity. | |
V1565 | Tanzisertib (CC-930) | 899805-25-5 | Tanzisertib (formerly known as CC-930,JNK-930, JNKI-1,CC 930) is a potent, specific andand orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications. | |
V2722 | Tanzisertib HCl (CC-930) | 899805-25-5 | Tanzisertib HCl (also known as CC-930) is a potent, specific andand orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications. | |
V81525 | TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) | TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) is a JNK peptide inhibitor. | ||
V0473 | TCS JNK 5a | 312917-14-9 | TCS JNK 5a (alsoknown asJNK Inhibitor IX; TCS JNK-5a) is a novel, highly selective and potent JNK (c-Jun N-terminal Kinase) inhibitor with potential antineoplastic activity. |